Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Viltolarsen: First Approval
Sohita Dhillon
Drugs (2020) Vol. 80, Iss. 10, pp. 1027-1031
Closed Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

Antisense technology: an overview and prospectus
Stanley T. Crooke, Brenda F. Baker, Rosanne M. Crooke, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 6, pp. 427-453
Closed Access | Times Cited: 504
Chemistry, structure and function of approved oligonucleotide therapeutics
Martin Egli, Muthiah Manoharan
Nucleic Acids Research (2023) Vol. 51, Iss. 6, pp. 2529-2573
Open Access | Times Cited: 400
RNA-based therapeutics: an overview and prospectus
Yiran Zhu, Liyuan Zhu, Xian Wang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 384
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Suzan M. Hammond, Annemieke Aartsma‐Rus, Sandra Alves, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 4
Open Access | Times Cited: 259
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
Maria Gagliardi, Ana Tari Ashizawa
Biomedicines (2021) Vol. 9, Iss. 4, pp. 433-433
Open Access | Times Cited: 141
Insight Into the Prospects for RNAi Therapy of Cancer
Zhili Tian, Guohui Liang, Kunli Cui, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 114
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Lara Moumné, Anne-Céline Marie, Nicolas Crouvezier
Pharmaceutics (2022) Vol. 14, Iss. 2, pp. 260-260
Open Access | Times Cited: 105
Adverse Drug Reactions and Toxicity of the Food and Drug Administration–Approved Antisense Oligonucleotide Drugs
Feryal Alhamadani, Kristy Zhang, Rajvi Parikh, et al.
Drug Metabolism and Disposition (2022) Vol. 50, Iss. 6, pp. 879-887
Open Access | Times Cited: 74
Antisense oligonucleotides: a novel Frontier in pharmacological strategy
Debora Collotta, Ilaria Bertocchi, E. Chiapello, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 61
Therapeutic approaches for Duchenne muscular dystrophy
Thomas C. Roberts, Matthew J. A. Wood, Kay E. Davies
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 11, pp. 917-934
Closed Access | Times Cited: 60
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases
Suxiang Chen, Saumya Nishanga Heendeniya, Bao T. Le, et al.
BioDrugs (2024) Vol. 38, Iss. 2, pp. 177-203
Open Access | Times Cited: 25
Advancements in clinical RNA therapeutics: Present developments and prospective outlooks
Phei Er Saw, Erwei Song
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101555-101555
Open Access | Times Cited: 20
Rapid and scalable personalized ASO screening in patient-derived organoids
John C. Means, Anabel Martinez‐Bengochea, Daniel Louiselle, et al.
Nature (2025) Vol. 638, Iss. 8049, pp. 237-243
Open Access | Times Cited: 5
RNA dysregulation in neurodegenerative diseases
Yini Li, Shuying Sun
The EMBO Journal (2025) Vol. 44, Iss. 3, pp. 613-638
Open Access | Times Cited: 3
Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches
Xiaofang Li, Jintao Xu, Shanshan Yao, et al.
Journal of Cachexia Sarcopenia and Muscle (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update
Chengmei Sun, Luoan Shen, Zheng Zhang, et al.
Genes (2020) Vol. 11, Iss. 8, pp. 837-837
Open Access | Times Cited: 137
2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
Othman Al Musaimi, Danah Al Shaer, Fernando Alberício, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 145-145
Open Access | Times Cited: 75
Nucleic Acid Drugs—Current Status, Issues, and Expectations for Exosomes
Yoji Yamada
Cancers (2021) Vol. 13, Iss. 19, pp. 5002-5002
Open Access | Times Cited: 68
2021 FDA TIDES (Peptides and Oligonucleotides) Harvest
Danah Al Shaer, Othman Al Musaimi, Fernando Alberício, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 222-222
Open Access | Times Cited: 64
Potential Therapeutic Strategies for Skeletal Muscle Atrophy
Li Huang, Ming Li, Chunyan Deng, et al.
Antioxidants (2022) Vol. 12, Iss. 1, pp. 44-44
Open Access | Times Cited: 52
CRISPR Therapeutics for Duchenne Muscular Dystrophy
Esra Erkut, Toshifumi Yokota
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1832-1832
Open Access | Times Cited: 42
Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice
Cody A. Desjardins, Monica Yao, John K. Hall, et al.
Nucleic Acids Research (2022) Vol. 50, Iss. 20, pp. 11401-11414
Open Access | Times Cited: 41
Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing
Bao T. Le, Sibasish Paul, Katarzyna Jastrzębska, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 36
Open Access | Times Cited: 40
Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity
Heyang Zhang, Jo Vandesompele, Kevin Braeckmans, et al.
Chemical Society Reviews (2023) Vol. 53, Iss. 1, pp. 317-360
Closed Access | Times Cited: 40
The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis
Wujun Chen, Jiazhen Xu, Yudong Wu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 9, pp. 2879-2896
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top